
In today’s briefing:
- Ming Yu Pharmaceutical (明宇制药) Pre-IPO Quick Comment: Meaningful Improvement to Incumbents
- Celltrion (068270 KS): Stellar 3Q Result; Poised for Accelerated Growth on Expanding Portfolio
- Eli Lilly’s Adverum Acquisition: What They Didn’t Say in the Press Release!
- Kymera Therapeutics Surges 46%: A New Oral Challenger To Dupixent?
- Lumexa Imaging Holdings, Inc. (LMRI): Steady IPO Debut for Imaging Company
- MTVA: New Date for Vanoglipel (DA-1241) Presented at AASLD
- Mirum Pharma’s $620M Bluejay Acquisition: Strategic Masterstroke or High-Stakes Misfire?
- Hybridan Small Cap Feast: 4 December 2025
- CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response
- Primer: UEM Edgenta Bhd (UEME MK) – Dec 2025

Ming Yu Pharmaceutical (明宇制药) Pre-IPO Quick Comment: Meaningful Improvement to Incumbents
- Ming Yu, a China-based clinical-stage biotech company, is looking to raise at least USD 100 million via a Hong Kong listing. MS, BOA, and CITIC are the joint book runners.
- In this note, we look at the company’s core products, MHB018A and MHB036C, and assess the selling point around the core product.
- We also look at the company’s pre-IPO investors and management team.
Celltrion (068270 KS): Stellar 3Q Result; Poised for Accelerated Growth on Expanding Portfolio
- Celltrion Inc (068270 KS) has reported 3Q25 result, with double-digit YoY growth in key parameters. Key parameters also improved sequentially. Stellar 3Q performance was powered by high-margin young products.
- In 4Q25, Celltrion is expected to achieve sequential revenue growth of at least 30%, the COGS ratio in the mid- 30% range, and the operating profit margin improving to 40%.
- Stable revenue from mature products and rapid growth from newly launched products should drive topline growth. With the merger effect ending in 3Q25, profitability should improve in 4Q.
Eli Lilly’s Adverum Acquisition: What They Didn’t Say in the Press Release!
- Eli Lilly isn’t slowing down.
- After a quarter filled with blockbuster drug launches, accelerated global uptake of Mounjaro and Zepbound, and $12 billion in quarterly product revenue, the pharma heavyweight has turned its attention to gene therapy.
- The Eli Lilly Adverum acquisition is now official, as announced on December 9, 2025.
Kymera Therapeutics Surges 46%: A New Oral Challenger To Dupixent?
- Kymera Therapeutics surged as much as 46% to a record high of $97.28 after announcing highly encouraging Phase 1b clinical data for its anti-inflammatory drug candidate, KT-621.
- The once-daily oral pill demonstrated significant reductions in key Type 2 inflammation biomarkers, including STAT6 and fractional exhaled nitric oxide (FeNO), and was well-tolerated with a favorable safety profile.
- These early findings have sparked investor enthusiasm, especially as KT-621 shows potential to rival injectable therapies like Regeneron’s Dupixent.
Lumexa Imaging Holdings, Inc. (LMRI): Steady IPO Debut for Imaging Company
- Lumexa priced 25mm shares at $18.50 and delivered a stable debut, reflecting disciplined valuation despite broad 2025 weakness in PE-backed IPOs.
- Strong oversubscription from long-only and healthcare-dedicated investors supported a solid open, with first-day trading remaining orderly and tightly ranged.
- Lumexa’s scaled outpatient imaging platform, strong payer mix, and superior margins position it favorably within a fragmented $140B market with substantial consolidation runway.
MTVA: New Date for Vanoglipel (DA-1241) Presented at AASLD
- In November 2025, MetaVia Inc. (MTVA) announced new positive data from the Phase 2a clinical trial of vanoglipel (DA-1241) was presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025.
- After 16 weeks of treatment, vanoglipel showed reductions in HbA1c of 0.37%, 0.41%, and 0.54% at weeks 4, 8, and 16, from a baseline of 6.99%.
- Vanoglipel also significantly decreased plasma ALT levels in subjects with baseline ALT between 40 and 200 U/L.
Mirum Pharma’s $620M Bluejay Acquisition: Strategic Masterstroke or High-Stakes Misfire?
- Mirum Pharmaceuticals is making big moves.
- In early December 2025, the company announced its plan to acquire privately held Bluejay Therapeutics in a deal worth up to $820 million.
- The proposed transaction includes $250 million in cash, $370 million in Mirum common stock, and up to $200 million in tiered sales-based milestones.
Hybridan Small Cap Feast: 4 December 2025
- Alien Metals 0.125p £11.6m (UFO.L) The minerals exploration and development company has reported that its joint venture partner, West Coast Silver Limited has announced that it has entered into a non-binding Memorandum of Understanding with Artemis Resources Limited to evaluate the potential for Artemis’ Radio Hill Processing Plant, located near Karratha, to process material sourced from West Coast’s Elizabeth Hill Silver Mine in the Pilbara.
- Digitalbox 4.75p £5.6m (DBOX.L) The mobile-first digital media business, with websites such as the Entertainment Daily, The Daily Mash, The Poke, The Tab and TV Guide updates on its Q4 period in 2025.
- The Company expects EBITDA for the FY December 2025 to be significantly ahead of expectations while revenue to be broadly in line.
CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response
- Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal (CRC), pancreatic, lung and breast cancers.
- The company’s primary indication is first line metastatic CRC in patients with Rat Sarcoma (RAS) mutations.
- Onvansertib is an oral Polo-like kinase 1 (PLK1)-selective inhibitor that has synergies with bevacizumab & various chemotherapy regimens.
Primer: UEM Edgenta Bhd (UEME MK) – Dec 2025
- Strong International Growth and Order Book: UEM Edgenta is successfully executing a strategy of international expansion, with over 90% of new contracts in 1H 2024 originating from Singapore, Taiwan, and the Middle East. This has bolstered its total order book to RM9.3 billion as of March 2025, providing significant revenue visibility.
- Resilient Business Model Amidst Margin Pressures: Despite recent quarterly losses attributed to higher operational costs and cyclical factors, the company demonstrates resilience through its diversified service offerings and long-term contracts, particularly in the essential healthcare and infrastructure sectors. Management expects a return to profitability driven by new contract contributions and cost management initiatives.
- Attractive Valuation with Turnaround Potential: The company trades at a significant discount to peers on key metrics like EV/Sales and EV/EBITDA. While recent earnings volatility is a concern, the combination of a robust order book, a strategic focus on technology and international growth, and a formal cost-saving program presents a compelling turnaround narrative.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

